Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Summary

Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy

Timeline

Start

2017-04-03

Primary completion

2019-11-13

Completion

2024-12-20

Publications

• Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domenech ED, Tucci A, Mannina D, Merli M, Salar A, Visco C, Esposito F, Bonomini L, Zucca E, Ferreri AJM, Raderer M. IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. Haematologica. 2023 Jun 1;108(6):1671-1675. doi: 10.3324/haematol.2022.281963. No abstract available.

Drugs

Indications